| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PDE4A |
| Uniprot No | P27815 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-647 aa |
| 活性数据 | MPLVDFFCETCSKPWLVGWWDQFKRMLNRELTHLSEMSRSGNQVSEYISTTFLDKQNEVEIPSPTMKEREKQQAPRPRPSQPPPPPVPHLQPMSQITGLKKLMHSNSLNNSNIPRFGVKTDQEELLAQELENLNKWGLNIFCVSDYAGGRSLTCIMYMIFQERDLLKKFRIPVDTMVTYMLTLEDHYHADVAYHNSLHAADVLQSTHVLLATPALDAVFTDLEILAALFAAAIHDVDHPGVSNQFLINTNSELALMYNDESVLENHHLAVGFKLLQEDNCDIFQNLSKRQRQSLRKMVIDMVLATDMSKHMTLLADLKTMVETKKVTSSGVLLLDNYSDRIQVLRNMVHCADLSNPTKPLELYRQWTDRIMAEFFQQGDRERERGMEISPMCDKHTASVEKSQVGFIDYIVHPLWETWADLVHPDAQEILDTLEDNRDWYYSAIRQSPSPPPEEESRGPGHPPLPDKFQFELTLEEEEEEEISMAQIPCTAQEALTAQGLSGVEEALDATIAWEASPAQESLEVMAQEASLEAELEAVYLTQQAQSTGSAPVAPDEFSSREEFVVAVSHSSPSALALQSPLLPAWRTLSVSEHAPGLPGLPSTAAEVEAQREHQAAKRACSACAGTFGEDTSALPAPGGGGSGGDPT |
| 分子量 | 98.6 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于重组人PDE4A蛋白的参考文献及简要摘要：
1. **"Structural basis for the design of selective phosphodiesterase 4A inhibitors"**
*Authors: Burgin AB, et al.*
**摘要**：该研究通过X射线晶体学解析了重组人PDE4A蛋白的催化结构域三维结构，基于结构设计了高选择性抑制剂，并验证了其对cAMP水解活性的抑制作用，为靶向PDE4A的药物开发提供了基础。
2. **"Expression and purification of recombinant human PDE4A in Escherichia coli for biochemical characterization"**
*Authors: Wang Y, et al.*
**摘要**：报道了一种高效表达重组人PDE4A蛋白的优化方法，利用大肠杆菌表达系统纯化功能性PDE4A，并通过酶动力学实验验证其活性，为大规模制备及药物筛选提供了技术方案。
3. **"Functional analysis of PDE4A splice variants in cAMP signaling"**
*Authors: Houslay MD, et al.*
**摘要**：研究利用重组表达的PDE4A不同剪接变体，揭示了其在细胞内cAMP动态调节中的特异性功能差异，表明PDE4A亚型可通过不同机制调控炎症相关信号通路。
4. **"Recombinant PDE4A as a therapeutic target in neurodegenerative disorders"**
*Authors: Zhang L, et al.*
**摘要**：通过体外和细胞模型验证重组人PDE4A蛋白活性，发现其抑制剂可缓解神经炎症和氧化应激，提示PDE4A可能是阿尔茨海默病等疾病的潜在治疗靶点。
*注：以上文献名称和作者为示例性内容，具体引用需根据实际发表的论文调整。建议通过PubMed或Web of Science以“recombinant human PDE4A”为关键词检索最新文献。*
**Recombinant human PDE4A protein** belongs to the phosphodiesterase 4 (PDE4) family, a group of enzymes that hydrolyze cyclic adenosine monophosphate (cAMP), a critical secondary messenger in cellular signaling. PDE4A, encoded by the *PDE4A* gene, is one of four subfamilies (A-D) within the PDE4 superfamily, characterized by conserved catalytic domains and unique N-terminal regulatory regions. It plays a key role in regulating cAMP levels, impacting processes like inflammation, neurotransmission, and immune responses. PDE4A is predominantly expressed in the brain, immune cells, and vascular tissues, making it a target for treating neurological, inflammatory, and respiratory disorders.
Recombinant PDE4A is produced via heterologous expression systems (e.g., *E. coli* or mammalian cells) for structural and functional studies. Its recombinant form allows researchers to investigate enzyme kinetics, inhibitor binding, and isoform-specific activities. Selective PDE4A inhibitors are explored for therapeutic applications, particularly in diseases like asthma, chronic obstructive pulmonary disease (COPD), and neurodegenerative conditions. However, challenges persist in achieving isoform specificity, as PDE4A shares high structural similarity with other PDE4 subfamilies, potentially leading to off-target effects. Recent advances in cryo-EM and X-ray crystallography have elucidated PDE4A’s 3D structure, aiding rational drug design. As a tool molecule, recombinant PDE4A also supports high-throughput screening for novel modulators, highlighting its dual role in basic research and pharmaceutical development.
×
